Balyasny Asset Management
CAPR icon

Balyasny Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Balyasny Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,000
Closed -$1.39M – 2952
2025
Q2 		$1.39M Buy
+140,000
New +$1.48M ﹤0.01% 1911

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management's CAPR Position: Q2 2026 in Review

Balyasny Asset Management increased its Capricor Therapeutics (CAPR) stake by 64% in Q2 2026, buying an estimated $5.75M and bringing the position to 486,836 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #985.

Balyasny Asset Management first reported a position in CAPR in Q1 2024 and has held it in 5 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Balyasny Asset Management held 486,836 shares of Capricor Therapeutics worth $11.7M as of Q2 2026.
  • Balyasny Asset Management bought 189,713 Capricor Therapeutics shares in Q2 2026, an estimated $5.75M.
  • Capricor Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #985 holding.
  • Balyasny Asset Management first reported a position in Capricor Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.